Carboplatin and Etoposide for Elderly Patients with Small-Cell Lung Cancer
Author Information
Author(s): K Matsui, N Masuda, M Fukuoka, T Yana, T Hirashima, T Komiya, M Kobayashi, M Kawahara, S Atagi, M Ogawara, S Negoro, S Kudoh, K Furuse
Primary Institution: Osaka Prefectural Habikino Hospital
Hypothesis
Can the Egorin's carboplatin dosing formula combined with oral etoposide effectively treat elderly patients with small-cell lung cancer?
Conclusion
The combination of carboplatin and oral etoposide is effective and tolerable for elderly patients with small-cell lung cancer.
Supporting Evidence
- The overall response rate was 81%.
- Median survival times were 15.1 months for limited-disease patients and 8.6 months for extensive-disease patients.
- Myelosuppression was the principal side effect observed.
- Two treatment-related deaths were noted in patients with extensive disease.
Takeaway
Doctors tested a new way to give chemotherapy to older people with lung cancer, and it worked well for many of them.
Methodology
A phase II trial evaluated the efficacy and toxicity of carboplatin and oral etoposide in 38 elderly patients with small-cell lung cancer.
Limitations
The study had a small sample size and included only patients over 70 years old.
Participant Demographics
Median age was 78 years, with 30 males and 8 females.
Want to read the original?
Access the complete publication on the publisher's website